Medivolve Inc. Logo

Medivolve Inc.

MEDV.NE

(1.2)
Stock Price

0,03 CAD

-879.33% ROA

219.42% ROE

-0.05x PER

Market Cap.

810.576,00 CAD

-10.61% DER

0% Yield

-796.99% NPM

Medivolve Inc. Stock Analysis

Medivolve Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medivolve Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-0.28x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (-57%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-1536.57%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-109.3%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Medivolve Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medivolve Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Medivolve Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medivolve Inc. Revenue
Year Revenue Growth
2006 0
2007 6.175 100%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -152.106 100%
2020 1.475.753 110.31%
2021 86.824.987 98.3%
2022 37.175.237 -133.56%
2023 1.024.048 -3530.22%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medivolve Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 1.520 100%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medivolve Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 0 0%
2008 1.192.524 100%
2009 1.810.103 34.12%
2010 2.052.341 11.8%
2011 1.968.714 -4.25%
2012 1.639.497 -20.08%
2013 1.621.847 -1.09%
2014 1.609.159 -0.79%
2015 956.065 -68.31%
2016 939.952 -1.71%
2017 3.275.058 71.3%
2018 878.308 -272.88%
2019 2.274.361 61.38%
2020 8.410.512 72.96%
2021 18.364.089 54.2%
2022 26.197.260 29.9%
2023 2.651.112 -888.16%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medivolve Inc. EBITDA
Year EBITDA Growth
2006 -134.478
2007 -138.699 3.04%
2008 -1.272.520 89.1%
2009 -1.792.719 29.02%
2010 -2.078.648 13.76%
2011 -2.079.245 0.03%
2012 -39.803 -5123.84%
2013 -1.584.439 97.49%
2014 -1.842.072 13.99%
2015 -842.028 -118.77%
2016 -1.352.048 37.72%
2017 -11.152.705 87.88%
2018 -1.286.981 -766.58%
2019 -2.381.952 45.97%
2020 -19.018.923 87.48%
2021 16.993.053 211.92%
2022 -927.062 1933%
2023 -2.035.448 54.45%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medivolve Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 6.175 100%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 -204 100%
2017 -2.242 90.9%
2018 0 0%
2019 -1.197.966 100%
2020 -4.501.065 73.38%
2021 36.569.100 112.31%
2022 14.385.554 -154.21%
2023 866.940 -1559.35%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medivolve Inc. Net Profit
Year Net Profit Growth
2006 -134.556
2007 -139.382 3.46%
2008 -1.266.124 88.99%
2009 -1.805.835 29.89%
2010 -2.044.126 11.66%
2011 -1.840.765 -11.05%
2012 -3.300.102 44.22%
2013 -5.891.023 43.98%
2014 -2.039.175 -188.89%
2015 -1.134.824 -79.69%
2016 -761.314 -49.06%
2017 3.167.908 124.03%
2018 -711.562 545.2%
2019 -2.718.245 73.82%
2020 -37.777.656 92.8%
2021 -6.610.524 -471.48%
2022 -18.365.334 64.01%
2023 -1.903.976 -864.58%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medivolve Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 -2
2007 -2 0%
2008 -13 92.31%
2009 -9 -44.44%
2010 -7 -28.57%
2011 -5 -75%
2012 -7 42.86%
2013 -13 46.15%
2014 -5 -225%
2015 -2 -100%
2016 -1 0%
2017 1 100%
2018 0 0%
2019 -1 100%
2020 -6 80%
2021 0 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medivolve Inc. Free Cashflow
Year Free Cashflow Growth
2006 -119.391
2007 -131.692 9.34%
2008 -1.333.173 90.12%
2009 -2.012.775 33.76%
2010 -3.138.702 35.87%
2011 -1.114.206 -181.7%
2012 -3.058.920 63.58%
2013 -2.583.483 -18.4%
2014 -631.673 -308.99%
2015 -169.145 -273.45%
2016 -1.076.765 84.29%
2017 3.473.934 131%
2018 -459.044 856.78%
2019 -4.378.763 89.52%
2020 -14.515.780 69.83%
2021 -9.365.008 -55%
2022 6.044.416 254.94%
2023 -734.916 922.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medivolve Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -107.203
2007 -119.692 10.43%
2008 -287.689 58.4%
2009 -801.411 64.1%
2010 -1.219.093 34.26%
2011 -1.114.206 -9.41%
2012 -1.571.342 29.09%
2013 -1.313.423 -19.64%
2014 -631.673 -107.93%
2015 -169.145 -273.45%
2016 -1.066.180 84.14%
2017 3.498.934 130.47%
2018 -384.044 1011.08%
2019 -4.378.763 91.23%
2020 -10.978.335 60.11%
2021 -9.322.326 -17.76%
2022 6.044.416 254.23%
2023 -734.916 922.46%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medivolve Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 12.188
2007 12.000 -1.57%
2008 1.045.484 98.85%
2009 1.211.364 13.69%
2010 1.919.609 36.9%
2011 0 0%
2012 1.487.578 100%
2013 1.270.060 -17.13%
2014 0 0%
2015 0 0%
2016 10.585 100%
2017 25.000 57.66%
2018 75.000 66.67%
2019 0 0%
2020 3.537.445 100%
2021 42.682 -8187.91%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medivolve Inc. Equity
Year Equity Growth
2006 -21.024
2007 389.759 105.39%
2008 2.021.372 80.72%
2009 8.116.548 75.1%
2010 6.857.663 -18.36%
2011 13.023.260 47.34%
2012 9.963.923 -30.7%
2013 4.090.545 -143.58%
2014 628.650 -550.69%
2015 -503.084 224.96%
2016 2.089.477 124.08%
2017 5.257.385 60.26%
2018 4.545.823 -15.65%
2019 1.984.478 -129.07%
2020 -10.014.002 119.82%
2021 17.808.665 156.23%
2022 326.262 -5358.39%
2023 -15.973.034 102.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medivolve Inc. Assets
Year Assets Growth
2006 16.477
2007 395.017 95.83%
2008 2.094.640 81.14%
2009 8.247.564 74.6%
2010 7.070.519 -16.65%
2011 13.308.664 46.87%
2012 10.772.692 -23.54%
2013 4.464.283 -141.31%
2014 1.295.528 -244.59%
2015 952.785 -35.97%
2016 2.221.232 57.11%
2017 5.297.905 58.07%
2018 4.581.026 -15.65%
2019 2.300.474 -99.13%
2020 19.131.246 87.98%
2021 59.295.417 67.74%
2022 18.818.419 -215.09%
2023 2.366.701 -695.13%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medivolve Inc. Liabilities
Year Liabilities Growth
2006 37.501
2007 5.258 -613.22%
2008 73.268 92.82%
2009 131.016 44.08%
2010 212.856 38.45%
2011 285.404 25.42%
2012 808.769 64.71%
2013 373.738 -116.4%
2014 666.878 43.96%
2015 1.455.869 54.19%
2016 131.755 -1004.98%
2017 40.520 -225.16%
2018 35.203 -15.1%
2019 315.996 88.86%
2020 29.145.248 98.92%
2021 41.486.752 29.75%
2022 18.492.157 -124.35%
2023 18.339.735 -0.83%

Medivolve Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.08
Net Income per Share
-0.61
Price to Earning Ratio
-0.05x
Price To Sales Ratio
0.39x
POCF Ratio
-0.28
PFCF Ratio
-0.28
Price to Book Ratio
-0.05
EV to Sales
0.81
EV Over EBITDA
-0.29
EV to Operating CashFlow
-0.58
EV to FreeCashFlow
-0.58
Earnings Yield
-20.3
FreeCashFlow Yield
-3.57
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
2.83
Graham NetNet
-0.63

Income Statement Metrics

Net Income per Share
-0.61
Income Quality
0.17
ROE
2.19
Return On Assets
-6.95
Return On Capital Employed
0.41
Net Income per EBT
2.65
EBT Per Ebit
0.95
Ebit per Revenue
-3.17
Effective Tax Rate
-1.73

Margins

Sales, General, & Administrative to Revenue
2.67
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.68
Operating Profit Margin
-3.17
Pretax Profit Margin
-3.01
Net Profit Margin
-7.97

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.11
Free CashFlow per Share
-0.11
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
1.27
Return on Tangible Assets
-8.79
Days Sales Outstanding
46.33
Days Payables Outstanding
4861.78
Days of Inventory on Hand
21.31
Receivables Turnover
7.88
Payables Turnover
0.08
Inventory Turnover
17.13
Capex per Share
0

Balance Sheet

Cash per Share
0,04
Book Value per Share
-0,58
Tangible Book Value per Share
-0.61
Shareholders Equity per Share
-0.58
Interest Debt per Share
0.07
Debt to Equity
-0.11
Debt to Assets
0.71
Net Debt to EBITDA
-0.15
Current Ratio
0.08
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-0.11
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.21
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
36520.5
Debt to Market Cap
2.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medivolve Inc. Dividends
Year Dividends Growth

Medivolve Inc. Profile

About Medivolve Inc.

Medivolve Inc. is a principal investment firm. It prefers to invest in healthcare technology, industrials, information technology. Medivolve Inc., formerly known as QuestCap Inc, was founded in 2005 and is based in Toronto, Canada.

CEO
Mr. David Preiner
Employee
25
Address
65 Queen Street West
Toronto, M5H 2M5

Medivolve Inc. Executives & BODs

Medivolve Inc. Executives & BODs
# Name Age
1 Mr. Neil Said
General Counsel
70
2 Mr. Aaron Atin
Consultant
70
3 Pamela Kennedy
Senior Advisor Government Affairs
70
4 Mr. David Preiner
President & Chief Executive Officer
70
5 Dominique Vaillancourt
Manager of Investor Relations
70
6 Mr. Indivar Pathak
Chief Operating Officer - Collection Sites
70

Medivolve Inc. Competitors